Results 31 to 40 of about 38,208 (195)
Journal of Clinical Oncology, 2019 PURPOSE Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified
J. Donadieu +45 more
semanticscholar +1 more source
Pulmonary Langerhans cell histiocytosis causing spontaneous bilateral pneumothorax in a child
The Egyptian Journal of Internal Medicine, 2015 Bilateral pneumothorax is very rare in childhood. Moreover, if it is due to pulmonary involvement of Langerhans cell histiocytosis, it is even rarer in childhood.
Anupam Patra +3 more
doaj +1 more source
SAGE Open Medical Case Reports, 2014 Objective: Langerhans cell histiocytosis is an unusual disorder of unknown etiology with heterogeneous clinical behaviors and variable outcomes. It can involve one or more organs or systems, but to our best knowledge, parotid glands involvement in ...
Xiaojun Yuan +4 more
doaj +1 more source
Rare Tumors, 2017 Langerhans cell sarcoma of the skin is a rare tumor with aggressive behavior. There are reports of Langerhans cell sarcoma involving the skin in patients with underlying systemic Langerhans cell histiocytosis.
Alejandro Peralta Soler +2 more
doaj +1 more source
Three cases of congenital self‐healing Langerhans cell histiocytosis with BRAF‐V600E mutation
JEADV Clinical Practice, 2022 Congenital self‐healing Langerhans cell histiocytosis (CSHLCH) is a rare variant of Langerhans cell histiocytosis characterised by the presence of skin lesions in the neonate and spontaneous self‐healing after a variable period of time.
Mar Ramírez‐Lluch +7 more
doaj +1 more source
Efficacy of BRAF-inhibitor therapy in BRAFV600E -mutated Adult Langerhans Cell Histiocytosis.
The Oncologist, 2020 Langerhans-cell histiocytosis (LCH) is a rare disease of unknown pathogenesis. To date, there is a lack of FDA-approved treatments in adult LCH to establish optimal first line therapy.
A. Hazim +15 more
semanticscholar +1 more source
Cancer immunology research, 2020 CSF1R promotes efficient Langerhans cell (LC) differentiation from hematopoietic progenitors and migration, which may be reduced by CSF1R kinase inhibition.
S. Lonardi +15 more
semanticscholar +1 more source
Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment
Cancer Science, 2018 Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by the accumulation of CD1a+/Langerin+ LCH cells and wide‐ranging organ involvement.
Masayuki Kobayashi, A. Tojo
semanticscholar +1 more source
Isolated Langerhans Histiocytosis in Thyroid: Thyroidectomy or Chemotherapy? [PDF]
Journal of Clinical and Diagnostic Research, 2015 Langerhans cell histiocytosis (LCH) is a rare disorder of mononuclear phagocytic system whose clinical presentation varies from the localised involvement of a single bone to a widely disseminated disease.
Anoop Attakkil +4 more
doaj +1 more source
Advances in Dermatology and Allergology, 2018 Langerhans cell histiocytosis is a rare clonal disease characterized by the proliferation of CD1a-positive immature dendritic cells. The purpose of this article was to present an updated review of recent advances in the pathogenesis, clinical features ...
Michalina Jezierska +4 more
semanticscholar +1 more source